MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Fallopian Tube Carcinosarcoma · Recurrent Female Reproductive System Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Ovarian Carcinosarcoma · Recurrent Platinum-Resistant Fallopian Tube Carcinoma · Recurrent Platinum-Resistant Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma · Recurrent Primary Peritoneal Carcinosarcoma · Refractory Fallopian Tube Carcinoma · Refractory Female Reproductive System Carcinoma · Refractory Ovarian Carcinoma · Refractory Primary Peritoneal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (Brenda J. Ernst, MD)

Study leads

Brenda J. Ernst, M.D.
Principal Investigator
Mayo Clinic

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Malignant Ovarian Epithelial Tumor · Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma

Abroad (travel likely)RecruitingPHASE2

Detroit, United States · Flint, United States

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian · Primary Peritoneal · Fallopian Tube Cancer

Abroad (travel likely)RecruitingPHASE3

Chongqing, China

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Ovarian Clear Cell Adenocarcinoma · Platinum-Sensitive Ovarian Carcinoma · Recurrent Endometrial Serous Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Buffalo, United States · Houston, United States

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Epithelial Ovarian Cancer · Primary Peritoneal · Fallopian Tube Cancer

Abroad (travel likely)RecruitingPHASE2

Phoenix, United States · Tucson, United States